Case Series: From Metastatic Cancer to Cancer-Free in Months (16 of Dr. William Makis’s published cases) (2025)

Peer-Reviewed Study · Massimaux (Substack), reporting cases published by William Makis MD on Substack and X · March 9, 2025

Massimaux (Substack) et al., 2025-03-09: Compilation of 16 patient accounts Makis published, with the ivermectin doses used in each: 1 mg/kg/day commonly, escalated to 2 mg/kg/day in several, and 72 mg/day in two. Published with the claim that all 16 reached no evidence of disease.

So they started the following regimen: Ivermectin 1 mg/kg/day which was increased within 3 weeks to 2 mg/kg/day Fenbendazole 1000 mg/day Melatonin 300 mg/day

Massimaux (Substack) et al., 2025-03-09: Compilation of 16 patient accounts Makis published, with the ivermectin doses used in each: 1 mg/kg/day commonly, escalated to 2 mg/kg/day in several, and 72 mg/day in two. Published with the claim that all 16 reached no evidence of disease. C3 + rule 11. PATIENT-REPORTED, NOT INDEPENDENTLY VERIFIED. Publisher: Massimaux (a third-party Substack), 2025-03-09, republishing Makis's own Substack/X testimonials; Makis's original protocol posts are paywalled. Doses as published per case: case 2 ivermectin 1 mg/kg/day with mebendazole 1500 mg/day (stage 3C colon, recurrence in nodes, negative PET January 2025); case 3 ivermectin 1 mg/kg/day increased within 3 weeks to 2 mg/kg/day with fenbendazole 1000 mg/day and melatonin 300 mg/day (stage 4 clear cell renal cell carcinoma, concurrent ipilimumab/nivolumab); case 6 72 mg (1 mg/kg/day) for 4 months (stage 4 prostate, single sacral metastasis); case 8 150 mg ivermectin (2.5 mg/kg/day per the text) added August 2024 to fenbendazole 444 mg and melatonin 100 mg (stage 4 cholangiocarcinoma); cases 11 and 13 2 mg/kg/day; case 15 1 mg/kg/day with fenbendazole 1200 mg/day, IV vitamin C, 35 radiation fractions and 7 chemotherapy cycles; case 16 72 mg ivermectin with fenbendazole 1000 mg 3 days on/4 off plus chemotherapy. Outcomes as reported by the patients/author: scan-based (CT/PET), marker-based (CEA, CA125, PSA) and patient report; no independent verification, no control group, no adjudication. Every one of these patients was also receiving conventional chemotherapy, radiation or immunotherapy, which the compilation states. Makis's declared conflicts: not stated in this compilation. Study type: uncontrolled series.